Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520353 | 0.85 | CYP11B1 (0.57) | CYP11B1CYP11B2WNT3ANPC1RAB9A | |
| SCHEMBL28103317 | 0.84 | RAB9A (0.52) | CYP11B1CYP11B2WNT3ANPC1RAB9A | |
| SCHEMBL28103661 | 0.79 | CYP17A1 (0.56) | CYP11B1CYP11B2WNT3ARAB9ASMN1; SMN2 | |
| SCHEMBL14355099 | 0.78 | CYP11B1 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL28103664 | 0.77 | CA2 (0.46) | RAB9ASLC22A12CA2 | |
| SCHEMBL14355076 | 0.75 | HPGDS (0.56) | CYP11B1CYP11B2NPC1SMN1; SMN2MAP2K3 | |
| SCHEMBL1178369 | 0.74 | CA2 (0.58) | RAB9ASMN1; SMN2CA2 | |
| SCHEMBL12533585 | 0.74 | RAB9A (0.58) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12303035 | 0.74 | WNT3A (0.82) | WNT3A | |
| Hydrochloric Acid SCHEMBL2673007 | 0.73 | CA2 (0.56) | RAB9ASMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243305-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE DISEASES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2018-08-30 | — | — | US | disclosed |
| US-7301029-B2 | Bipyridine Derivatives | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20050085642-A1 | Novel bipyridine derivatives | SANKIO CHEMICAL CO., LTD. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085642-A1 | Novel bipyridine derivatives | PFAS, CBR3, Q6ZSR9 | CYP11B1 2629/4885CYP11B2 2638/4885WNT3A 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.